Nyssen, Olga P.Montes, NuriaPérez Aísa, ÁngelesMartínez Domínguez, Samuel J.Tejedor Tejada, JavierLucendo, Alfredo J.Huguet, Jose M.Garre, AnaBujanda, LuisPajares, Ramónet al.2026-06-232026-06-232025Nyssen, O. P., Montes, N., Pérez‐Aísa, Á., Martínez‐Domínguez, S. J., Tejedor‐Tejada, J., Lucendo, A. J., Huguet, J. M., Garre, A., Bujanda, L., Pabón‐Carrasco, M., Castro‐Fernández, M., Perona, M., Ortiz‐Polo, I., Núñez, Ó., Marcos, M. S., Gómez Rodríguez, B. J., Loro, A. M., Bermejo, F., Barrio, J., … the Hp‐EuReg investigators. (2025). Effectiveness and safety of first‐line non‐bismuth quadruple concomitant therapy versus single‐capsule bismuth quadruple therapy. Alimentary Pharmacology & Therapeutics, 62(8), 809-820. https://doi.org/10.1111/apt.702610269-2813https://hdl.handle.net/11268/17177The V Spanish Consensus Conference on Helicobacter pylori recommended either a 14-day non-bismuth quadruple concomitant therapy (CT: proton pump inhibitor [PPI], clarithromycin, amoxicillin, and metronidazole) or a 10-day bismuth-containing quadruple therapy (Sc-BQT: PPI, bismuth, tetracycline, and metronidazole in a single capsule). The relative advantages of each remain uncertain. Sc-BQT is more effective, better tolerated, and more broadly applicable than 14-day CT. Both regimens achieved ≥ 90% success, but Sc-BQT's stewardship-friendly profile further supports its use as first-line therapy for H. pylori eradication.engEnfermedades Inflamatorias del IntestinoEnfermedades Autoinmunesjournal article10.1111/apt.70261embargoed accessCiencias médicasInmunologíaMicrobiologíaGoal 3: Ensure healthy lives and promote well-being for all at all ages